Back to Search Start Over

Outcomes and adverse events in older acute lymphoblastic Leukemia patients treated with a pediatric-inspired protocol with Pegylated or native Asparaginase

Authors :
Maria Agustina Perusini
Claire Andrews
Eshetu G. Atenafu
Vikas Gupta
Dawn Maze
Andre C. Schuh
Karen WL. Yee
Aniket Bankar
Marta B. Davidson
Guillaume Richard-Carpentier
Steven M. Chan
Jad Sibai
Aaron D. Schimmer
Mark D. Minden
Hassan Sibai
Source :
Hematology, Vol 29, Iss 1 (2024)
Publication Year :
2024
Publisher :
Taylor & Francis Group, 2024.

Abstract

ABSTRACTThis retrospective report presents the outcomes and adverse events (AEs) observed in 73 patients aged 60 years or older diagnosed with Philadelphia Chromosome-negative Acute Lymphoblastic Leukemia (Ph-negative ALL) treated with a pediatric-inspired protocol incorporating either Pegylated (PEG-ASP) or Native Asparaginase (EC-ASP). Notably, 61% of patients experienced AEs of Grade III-IV severity. The most prevalent AEs included thrombosis (35.6%), febrile neutropenia (38.4%), and transaminitis (34.2%). AEs did not translate into significant differences concerning overall survival, leukemia-free survival, or early mortality. Furthermore, we observed a reduction in early mortality rates (11% vs. 20%) and an increase in median overall survival (54 vs. 48 months) compared to our previous data. These findings suggest that the utilization of a pediatric-inspired chemotherapy protocol, with ASP, is an effective and well-tolerated therapeutic option for older patients with Ph-negative ALL. However, it emphasizes the importance of diligent monitoring and close follow-up throughout treatment.

Details

Language :
English
ISSN :
16078454
Volume :
29
Issue :
1
Database :
Directory of Open Access Journals
Journal :
Hematology
Publication Type :
Academic Journal
Accession number :
edsdoj.860fe86b5d6c425b93b7c8cf45f165fa
Document Type :
article
Full Text :
https://doi.org/10.1080/16078454.2024.2329027